Agent for treatment of hepatitis, toxoplasmosis, cytomegaloviral infection and influenza

FIELD: medicine, in particular agent for treatment of hepatitis, toxoplasmosis, cytomegaloviral infection and influenza.

SUBSTANCE: claimed agent contains physiological saline for intravenous administration, comprising hydrogen peroxide, 0.2 % riboxine solution and decoction of liquorice roots in specific ratio.

EFFECT: non-toxic and effective agent for treatment of abovementioned diseases.

7 ex

 

The invention relates to medicine, in particular to the means for the treatment of hepatitis, or toxoplasmosis or cytomegalovirus infection, or flu.

There is a method of treatment of chronic hepatitis b by introducing the patient of sinapore, prednisolone, hydrocortisone. Chronic hepatitis. Discussion (transcript of discussion at the "Round table") - "Therapeutic archives", 1982, No. 12, p.123-124).

However, the known method the treatment of patients with long - up to 6-7 months, and sometimes longer, with prolonged severe inflammation of the liver often turn into cirrhosis of the liver.

Known from the patent literature method for the treatment of cirrhosis of the liver surgery using infusate, which includes 200 ml aminosteril-N-heparin, 200 ml of 20-30%glucose solution, 15-20 ml of 5-10%solution of ascorbic acid 10-15 ml. Riboxin, 50 ml of 20%albumin solution and 2 ml of goparcapetema. This infusion is performed in 3-5 days 2-3 hours each day (see U.S. Pat. Of the Russian Federation No. 2165775, IPC a 61 K 38/00, publ. 27.04.2002,).

There is a method of treatment of viral hepatitis by using pathogenetic therapy, including prodigiozan, thymalin, pyrogenes, splenin, decaris and T-activin (Cherednichenko T.V. 2nd all-Union Congress of infectious diseases. Tashkent: Medicine, 1981, s-294).

However, the treatment of patients with viral hepatitis pyrogen is om and prodigiozana often leads to an increased hepatocytolysis, form of intoxication, temperature reaction, gepatomegalia, increased jaundice and Alt-enzymes.

Doubt and efficiency in the use of adjuvant in relieving acute and protracted convalescence in viral hepatitis. Great difficulties arise in assessing the effectiveness of splenin in the treatment of viral hepatitis, because this drug was used in the initial stage of the disease. Not be considered valid purpose in patients with viral hepatitis of levamisole, because it often increases the Alt and title HBS AR with HBV. Believe that levamisole indirectly causes enhanced lysis of infected hepatocytes. Its repeated application in a dose of 2 mg/kg causes serious and even potentially life-threatening adverse reactions hematologic and not hematological character.

Requires further research and generalizations of the method of treatment of viral hepatitis T-activin.

In the available literature there is no information about the preparations and methods of treatment of toxoplasmosis.

There is a method of treatment of cytomegalovirus infection in women with recurrent pregnancy loss pregnancy, including the use of drugs: ganciclovir(Cymevene), foscarnet, acyclovir. However, it has the following disadvantages: first, these drugs are usually used at citomegalovirus the red infection in patients with HIV infection and have side effects: nausea, vomiting, diarrhea, headache, itching, rash, leukopenia, neutropenia, anemia, thrombocytopenia, deposits in the bone marrow(foscarnet), which subsequently can affect the overall status of women, for her coming pregnancy and the fetus. The way of introducing them, usually intravenously. During treatment with acyclovir was showing marked resistance to cytomegalovirus.

There is a method of treatment of cytomegalovirus infection in women with recurrent pregnancy loss pregnancy, including the effects of Immunostimulants (decaris, T-activin). However, this method has the following disadvantages: itching, leukopenia, agranulocytosis, thrombocytopenia, nausea, vomiting and lack of consideration of the state of the immune system (see Daedalian L.G. Obstetric clinical management of women with recurrent pregnancy loss pregnancy, complicated by cytomegalovirus infection. Sat. scientific papers. Prevention, diagnosis and treatment of women with miscarriage and medical care for their children. - M., 1990, s-102).

In domestic and international medical practice today as anti-influenza drugs are used only two - amantadine and close its structural analog - rimantadine. (Y.A. novels and other Chemoprophylaxis of influenza amantadine. L., 1971, s-230).

However, these drugs are deacti the us, in the treatment of influenza type C. They are toxic. Their use in humans is accompanied by side effects of these drugs on the Central nervous system (insomnia, headache. the lower concentration, vomiting). In addition, the widespread use of rimantadine and amantadine for the treatment of patients with influenza And led to the emergence of strains of influenza viruses that are resistant to these drugs.

Influenza viruses a and b differ significantly from each other on antigenic and biological properties. Therefore, the antiviral activity of drugs used to treat influenza a, does not imply the possibility of its use in influenza Century the Exception is the drug Arbidol (see U.S. Pat. Of the Russian Federation No. 2008004, IPC And 61 To 31/405, bull. No. 4, 1994).

The objective of the invention is the expansion of the means of influence on a living organism, namely the development of tools for the treatment of hepatitis, or toxoplasmosis or cytomegalovirus infection, or flu.

The problem is solved by the use of means for the treatment of hepatitis, or toxoplasmosis or cytomegalovirus infection, or flu, which is a saline solution for intravenous hydrogen peroxide, 0.2% solution of Riboxin and a decoction of licorice roots in the following ratio of ingredients, ml/l:

The peroxidefrom 0.6 to 1.25
Riboxin25,0-50,0
A decoction of licorice roots5,0-10,0
SalineUp to 1000

The values of the components shown above are optimal to achieve maximum therapeutic effect.

If you take the hydrogen peroxide less than 0.6 ml/l of 0.2% solution of Riboxin less 25,0 ml/l, and a decoction of licorice roots less than 5.0 ml/l 1000 ml of physiological solution, applying the tools to a therapeutic effect. This is confirmed by an enzyme immunoassay studies proving that this concentration of funds does not change the titers of antibodies, the immunoglobulins in the blood.

If you take the hydrogen peroxide more than 1.25 ml/l of 0.2% solution of Riboxin more to 50.0 ml/l, and a decoction of licorice roots more than 10.0 ml/l 1000 ml of saline, intravenous administration tools there is fibrosis of blood vessels. This is confirmed by experimental studies on human volunteers.

The above statements indicate causation amounts of each component funds achievable technical result(therapeutic effect).

The quantitative content of the components selected experienced way is.

In practical medicine apply hydrogen peroxide solution (3%) as a disinfectant and deodorizing tool for washing and rinsing with stomatitis, sore throat, gynecological diseases and other (Mashkovsky PPM Medicines, p.ii. M: Medicine. 1978, s-341). It is clear colorless liquid with no odor or with a weak peculiar smell, slightly acid reaction. Quickly decomposes in the light, when heated in contact with the alkali, oxidizing and reducing substances, releasing oxygen.

On the basis of a large number of laboratory and clinical studies, it was found that using intravenous infusion of hydrogen peroxide can successfully fight bacterial, fungal, parasitic and viral infections, as well as to stimulate the immune system and inhibiting the growth of tumors. However, it is noted that during the infusion of the peroxide solution should not be mixed with other drugs (see Udupa. The healing properties of hydrogen peroxide. St. Petersburg: Piter, 1998, s).

Licorice root, in medical practice used as an expectorant (tinctures). From the roots and rhizomes of licorice get a number of drugs Liquiritin"granules "Flirtin"possessing anti-inflammatory activity. (Mashkovsky PPM Dosage what s means. Division I, M: Medicine. S-326).

Riboxin used intravenously stimulates the heart muscle; used as a psychotropic drug. Riboxin, being a nuke, can penetrate into the cells and improves the energy balance of a myocardium. There is evidence of the ability of Riboxin to increase the activity of some enzymes, stimulate the synthesis of nucleotides, to have a positive effect on metabolic processes in the myocardium and improve coronary circulation. Also prescribe the drug for liver diseases, there is evidence of improvement of visual functions in patients with glaucoma (see Mashkovsky PPM Medicines. t.ii, M.: OOO "New wave". 2002. s).

First proposed to apply an intravenous mixture of hydrogen peroxide, decoction of licorice roots and Riboxin as a means to treat a number of diseases: hepatitis, or toxoplasmosis or cytomegalovirus infection, or flu.

The licorice decoction prepared from dried powdered rhizomes of licorice. At the rate of 10 g per one liter of distilled water. Boil for 5-8 minutes on low heat, infused to cool the broth. Filtered through coarse, then a medical filter, poured into the flask 30-50 ml, sterilized at a temperature of 100°With 30 minutes. The broth is kept at a temperature of 2-4°C for 8 months.

Composition 1.

To obtain 1 liter of a working main) solution of the stated means, you need to take the hydrogen peroxide, 0.6 ml, plus a 0.2% solution of Riboxin 25,0 ml of decoction of licorice roots of 5.0 ml and add 969,4 ml standard physiological solution.

Part 2

To obtain 1 liter of the working (primary) solution funds, you need to take hydrogen peroxide 0,975 ml, plus a 0.2% solution of Riboxin of 37.5 ml of decoction of licorice roots of 7.5 ml and add 954,025 ml standard physiological solution.

Part 3.

To obtain 1 liter of the working (primary) solution funds, you need to take hydrogen peroxide 1.25 ml, plus a 0.2% solution of Riboxin of 50.0 ml of decoction of licorice roots 10.0 ml and add 938,75 ml standard physiological solution.

The drug was prepared by simple mixing of the components prior to introduction into a vein of the patient. The drug is injected repeatedly in direct relation to the severity of the disease. Treatment rates for 10-20 injections, with a rate of 40-60 drops per minute, after 3-4 days.

The invention is illustrated by the following examples of treatment of diseases by volunteers.

Example 1. Freestyle Solyakov I., born in 1963 Diagnosed with Hepatitis C. the treatment offered by the drug (composition 1) was 18 intravenous infusion with a speed of 50 drops per minute. In the treatment of subjective and objective patient's condition is normalized. The patient has recovered. The diagnosis has been removed.

Example 2. The patient In the ROVA M 1965 born in the Diagnosis of cytomegalovirus infection, toxoplasmosis, suffers from habitual miscarriage. The course of treatment offered by the drug (composition 2) was 20 intravenous injections. In the normal course of pregnancy, physiological birth, was born a healthy child.

Example 3. Patient Diatlovo, born in 1946 disability group II after the flue And, tremor of the limbs. The course of treatment offered by the drug amounted to 20 intravenous injections. As a result of treatment with the drug (composition 3) the condition has improved, has a disability group III, works.

Example 4. Patient Ryzhova M born in 1965 Infertility Diagnosis II degree, toxoplasmosis, cytomegalovirus infection. The course of treatment offered by the drug (composition 1) was 20 intravenous injections. As a result of treatment the diagnosis has been removed.

Example 5. Patient Permyakova, NV, 21 years. Diagnosis: Hepatitis D. (comp) treatment offered by the drug (composition 2) was 15 intravenous infusion with a speed of 50 drops per minute in 4 days. 1 month course was repeated 5 IV every 4 days. In the treatment of subjective and objective patient's condition is normalized. The patient recovered. The diagnosis has been removed.

6. Patient Galagan, L.P. 47 years. Diagnosis: Influenza V (comp). The course of treatment offered by the drug (composition 3) was 12 intravenous infusion of 20 ml with a speed of 50 drops per minute every 4 days. The result is a complete cure. The patient has recovered. The diagnosis has been removed.

7. Sick of Petrishenko O.A. 18 years. Diagnosis: Influenza A (comp). The treatment was carried out in the period of the epidemic on the background of high temperature. The course of treatment offered by the drug (composition 1) was 12 intravenous infusion of 200 ml at a speed of 45 drops per minute 3 days in a row. The result is a complete cure. The diagnosis has been removed.

Thus, the proposed remedy for the treatment of hepatitis, or toxoplasmosis or cytomegalovirus infection, or flu is an effective potential drug-drug, non-toxic as it contains in its structure studied and tested in practical health care components and may, after further in-depth study to find wide application in practical medicine. The method of preparation tools does not require sophisticated equipment and hard drugs, which indicates the industrial applicability of the invention.

The treatment for hepatitis, toxoplasmosis, cytomegaloviruses infection and flu, characterized in that it is a physiological intravenous solution containing hydrogen peroxide, 0.2% solution of Riboxin and a decoction of licorice roots in the following ratio of ingredients, ml/l:

The peroxidefrom 0.6 to 1.25
0.2% solution of Riboxin25,0-50,0
A decoction of licorice roots5,0-10,0
SalineUp to 1000



 

Same patents:

FIELD: microbiology.

SUBSTANCE: claimed method includes providing of coccidial oocysts from fecal suspension, homogenization of fecal suspension, oocyst separation from fecal remainders of organic substances by salt flotation with sodium sulfate and other floating agents, oocyst sporulation using hydrogen peroxide and air barbotage, bleaching of sporulated oocysts, washing of bleached oocysts, concentration of sterile washed oocysts and blending of coccidial oocyst concentrates of various species to produce vaccines.

EFFECT: vaccines of high quality without toxic admixtures.

3 dwg

FIELD: medicine, veterinary science.

SUBSTANCE: a new group of compounds, such as: 1) 1.3-benzodixole-5-β-nitroethylene

, 2) 1.3-benzodioxole-5-β-nitropropylene

, 3)benzimidazole-5-β-nitropropylene

, 4) 2-methylbenzimidazole-5-β-nitroethylene

, 5) benzoxazole-5-β-nitroethylene

, 6) 2-methylbenzoxazole-5-β-nitropropylene

has been suggested to protect against the agents of bacterial, protozoan and fungoid nature. Compounds are being the derivatives of heteronitroalkenes (dioxoles, oxazoles, imidazoles) with below-mentioned structural formulas being efficient to gram-positive bacteria and gram-negative aerobes, fungi of Candida, Trichophyton and other types, trichomonads. They could be applied at treating wound infections, fungoid lesions, septic states, pneumonia, trachoma, ornithosis, salmonellosis.

EFFECT: higher efficiency of protection.

5 cl, 5 tbl

FIELD: medicine.

SUBSTANCE: invention proposes an agent for treatment of toxoplasmosis. Agent represents willow bark an aqueous extract prepared by method of thermal treatment in the ratio bark : water = 1:10, or willow bark powder. Invention expands assortment of agents of indicated prescription and provides treatment of patients with toxoplasmosis being among them with prevalent myocardium damage.

EFFECT: valuable medicinal properties of agent.

2 ex

The invention relates to medicine, namely to dermatology, and can be used for treatment of sexually transmitted infections
The invention relates to medicine, in particular to novel solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, to a method for the production of specified pharmaceutical compositions for the treatment of leishmaniasis specified pharmaceutical composition to a combination that includes the specified solid pharmaceutical composition, an antiemetic and/or antidiarrheal agent

The invention relates to medicine, in particular to venereology, and for the treatment of trichomoniasis

FIELD: medicine, biotechnology, healthy medical and veterinary preparations.

SUBSTANCE: claimed method includes exposing of aqueous isotonic solution of sugar-containing raw materials such as mixture of glucose and fructose in mass ratio of 1:1 with gamma-irradiation in absorbed dose of 25-40 kGy.

EFFECT: agent of standard composition with high antiviral and hepatoprotective action.

2 tbl, 2 ex

FIELD: medicine, neurology, virology.

SUBSTANCE: invention relates to treatment of neurological diseases caused by herpes virus, such as Bell's paralysis, Hunt's disease, herpetic encephalitis accompanying with damage of cerebral nerves. Invention involves using 1,4-dihydropyridine blockers of calcium channels, such as felodipine, nifedipine, nimodipine, nisodipine being taken preferably in combination with herpes virus antagonist. Invention provides repairing damaged cerebral nerves by topical expanding arteriols and recovery of local microcirculation based on specific competitive interaction of definite groups of calcium blockers of 1,4-dihydropyridine type with vasoconstrictor endothelin.

EFFECT: enhanced effectiveness of treatment.

47 cl, 2 dwg, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a cycloferon-containing medicinal agent used in prophylaxis and treatment of influenza and acute respiratory diseases, herpetic infection, chronic viral hepatitis B and C and prophylaxis of oncological diseases. Agent comprises a physiological solution in the following ratio of components: 10-29 - 10-2 mg of cycloferon in 1 ml of physiological solution. Also, invention relates to a method for preparing this medicinal agent. Proposed medicinal agent enhances antiviral and antitumor activity of natural killers by 1.8-fold, not less.

EFFECT: improved preparing and using method, valuable medicinal properties of agent.

7 cl, 1 dwg, 19 ex

FIELD: veterinary science.

SUBSTANCE: it is necessary to inject birch bark extract for the animal at the dosage of 20 or 40 mg/kg body weight. The present innovation enables to increase leukocytic immunocompetence that, in its turn, prevents viral proliferation and disease relapses.

EFFECT: higher efficiency of therapy.

2 cl, 1 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: the suggested strain refers to DNA-containing Adenoviridae type being of cubic type of symmetry, has no supercapsid membrane, virions sizes - 70-80 nm, shape - icosahedral. Moreover, it is resistant to the temperature of 56°C for 30 min, not less, and to the action of both ether and chloroform. It is inactivated with formalin, theotropin, dimer ethylenimine. The strain is cultivated in hepatic cell culture of hen's embryos, about 72-96 h after infection it causes characteristic foci of granulation (cells' rounding), the formation of separate rounded cells and foci of cell degeneration. Viral titer is within 105.5 TCD50/ml. The strain enables to reproduce different forms of the disease mentioned for experimental investigations, it is highly useful for manufacturing certain diagnostic kits and vaccines, moreover, being of high antigenic and immunogenic activity.

EFFECT: higher efficiency.

2 ex

Antiviral substance // 2276988

FIELD: medicine, virology, pharmacology.

SUBSTANCE: invention relates to an antiviral substance based on hemolymph of insects of subclass Pterigota. This substance is prepared by activation of immune system of insects, collection of hemolymph and the following treatment of prepared hemolymph by centrifugation, chromatography of supernatant, elution of hydrophobic components sobbed on column. Prepared eluate comprises a mixture of hydrophobic components possessing with an antiviral activity. Invention provides the direct antiviral effect and enhances resistance of body cells to viral infection by virus disruption or blocking its replication, or by other method.

EFFECT: improved preparing method, valuable antiviral properties of substance.

41 cl, 1 tbl, 1 dwg, 1 ex

FIELD: immunology, molecular biology.

SUBSTANCE: invention relates to a method for presentation of viral antigens of the host immune system based on proteasome-mediated technology designated for development of methods of biological protection. Method involves using recombinant plasmids pCI-neo-ODS-nsP1, pCI-neo-ODS-E2-L and pCI-neo-ODS-E2-M. Recombinant plasmids pCI-neo-ODS-nsP1, pCI-neo-ODS-E2-L and pCI-neo-ODS-E2-M are prepared by the successive cloning gene-equivalents of nonstructural protein nsP1, L and M fragments of structural protein E2 of virus VEL, respectively, as components of gene encoding enzyme ornitine decarboxylase being firstly into prokaryotic plasmid vector pET-23b and then into eucaryotic plasmid vector pCI-neo. The advantage of invention involves the development of polynucleotide vaccines inducing the cell-mediated immune response. The proposed invention represents the firstly developed in Russian Federation method of DNA vaccination based on using proteasome-mediated technology as result of molecular-biological and immunological investigations.

EFFECT: improved method for presentation of antigens.

4 tbl, 1 ex

FIELD: organic chemistry, biochemistry, medicine.

SUBSTANCE: invention relates to a new biologically active compound of 4-oxoquinoline that is useful as an anti-HIV agent and to its pharmaceutically acceptable salt. Invention describes an anti-HIV agent comprising compound of 4-oxoquinoline represented by the following formula [I] or its pharmaceutically acceptable salt as an active component wherein ring Cy represents phenyl group, naphthyl group or pyridyl group and each this group is substituted optionally with 1-5 substituted chosen from the following group A wherein A represents the group consisting of cyano-group, phenyl group, nitro-group, halogen atom, (C1-C4)-alkyl group, halogen-(C1-C4)-alkyl group, halogen-(C1-C4)-alkoxy-group, -ORa1, -SRa1, -NRa1Ra2, -CONRa1Ra2, -SO2NRa1Ra2, -NRa1CORa3, -SO2Ra3, -NRa1SO2Ra3 and -COORa1 wherein Ra1 and Ra2 are similar or different and each represents hydrogen atom, (C1-C4)-alkyl group or benzyl group, and Ra3 represents (C1-C4)-alkyl group; R1 represent a substitute chosen from the following group B, or (C1-C10)-alkyl group optionally substituted with 1-3 substitutes chosen from halogen atom and the following group B wherein the group B represents the group consisting of phenyl group optionally substituted with phenyl group or 1-5 halogen atoms; (C3-C6)-cycloalkyl group, imidazolyl group, benzothiophenyl group, thiazolyl group optionally substituted with 1-3 (C1-C6)-alkyl groups, morpholinyl group, pyridyl group, -ORa4, -SRa4, -NRa4Ra5, -CONRa4Ra5, -SO2NRa4Ra5, -CORa6, -NRa4CORa6, -SO2Ra6, -NRa4SO2Ra6, -COORa4 and -NRa5COORa6 wherein Ra4 and Ra5 are similar or different and each represents hydrogen atom, (C1-C4)-alkyl group or phenyl group; Ra6 represents (C1-C4)-alkyl group; R2 represents hydrogen atom or (C1-C4)-alkyl group; R31 represents hydrogen atom, cyano-group, hydroxy-group, halogen atom or (C1-C4)-alkoxy-group; X represents -C-R32, and Y represents -C-R33 or nitrogen atom wherein R32 and R33 are similar or different and each represents hydrogen atom, cyano-group, halogen atom, pyrrolidinyl group, (C1-C10)-alkyl group optionally substituted with 1-3 halogen atoms, -ORa7, -SRa7, -NRa7Ra8, -NRa7CORa9, -COORa10 or -N=CH-NRa10Ra11 wherein Ra7 and Ra8 are similar or different and each represents hydrogen atom, phenyl group or (C1-C10)-alkyl group optionally substituted with (C3-C6)-cycloalkyl group or hydroxy-group; Ra9 represents (C1-C4)-alkyl group and Ra10 and Ra11 are similar or different and each represents hydrogen atom or (C1-C4)-alkyl group. Also, invention describes compound of the formula (III) given in the invention description, integrase inhibitor, antiviral agent, ant-HIV composition, anti-HIV agent, using compound of 4-oxoqionoline, method for inhibition of integrase activity, method for prophylaxis or treatment of viral infectious disease, pharmaceutical composition used for inhibition of integrase activity, antiviral composition and commercial package (variants). Invention provides the development of a pharmaceutical agent possessing inhibitory effect on activity of integrase.

EFFECT: valuable medicinal properties of compound, agent and composition.

40 cl, 7 tbl, 250 ex

FIELD: medicine.

SUBSTANCE: method involves applying antiherpetic therapy using Phamcyclovir. Then, Trental is sequentially introduced during 5 days with 2-5 ml of cerebrolysin being concurrently intratissularly introduced behind mastoid process tip. Mexidol is administered for 10 days. The treatment is finished by introducing Polyoxydonium.

EFFECT: combined microcirculation improvement; high neurotrophic and antioxidant activity; secondary immune deficiency adjustment; eliminated labyrinth hydrops.

FIELD: immunology, biotechnology.

SUBSTANCE: invention describes antibody and its fragments neutralizing rabies virus and a method for treatment of patient subjected for effect of rabies virus by using indicated antibody and its fragment. Invention discloses variants of isolated nucleic acids encoding polypeptides carrying light and heavy chain of antibody, respectively. Also, invention describes expressing vector carrying at least one of indicated nucleic acids. Using this invention enhances span-life of patients after effect with rabies virus on them and can be used in corresponding prophylactic therapy of such patients.

EFFECT: valuable medicinal properties of antibody and nucleic acid.

14 cl, 1 dwg, 1 tbl, 2 ex

FIELD: pharmaceutical industry, in particular production of hepatothropic drug based on artichoke polyphenols.

SUBSTANCE: claimed method includes breakage of fresh artichoke leaves, treatment with hot steam for certain time; two-step extraction with hot water under specific conditions, extract separation from solvent cake, concentration of artichoke aqueous extract in vacuum to produce syrup-like extract. Obtained syrup-like extract is blended with filler, detacher and lubricant in specific component ratio.

EFFECT: method of increased yield; biologically active substances of improved stability; reduced raw material and extractant consumption; capsulated hepatothropic drug with high therapeutic activity and prolonged storage time.

10 cl, 8 ex

FIELD: medicine, biotechnology, healthy medical and veterinary preparations.

SUBSTANCE: claimed method includes exposing of aqueous isotonic solution of sugar-containing raw materials such as mixture of glucose and fructose in mass ratio of 1:1 with gamma-irradiation in absorbed dose of 25-40 kGy.

EFFECT: agent of standard composition with high antiviral and hepatoprotective action.

2 tbl, 2 ex

FIELD: biology, medicine.

SUBSTANCE: invention relates to cartiotrofin (CT-1) expression enhancing in process of liver regeneration which consists with maximal hepatocyte proliferation. Also invention relates to application of CT-1 and composition based on the same as stimulator of liver regeneration, as well as hepatoprotective effect of CT-1 in various models of acute liver lesions.

EFFECT: application of CT-1 to improve liver functions at various pathologies thereof.

10 cl, 14 ex, 13 dwg

FIELD: medicine, hepatology.

SUBSTANCE: at entering a hospital, one should detect patient's percentage content of lymphocytes in blood, and at its value being under 18% it is necessary to inject myelopid, every other day, 5 injections/course. Then comes conventional therapy of the above-mentioned disease. The innovation provides earlier prescription of immunocorrecting preparation as myelopid at acute period of the disease in question due to simple, objective criterion of individual necessity for myelopid prescription.

EFFECT: higher efficiency of therapy.

1 cl, 3 ex

Up!